Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M1 receptor function in the central nervous system

ACS Chemical Neuroscience

Volumn 1, Issue 2, 2010, Pages 104-121

  Lebois, Evan P ^a   Bridges, Thomas M ^a   Lewis, L Michelle ^a   Dawson, Eric S ^a,b   Kane, Alexander S ^a,b   Xiang, Zixiu ^a,b   Jadhav, Satyawan B ^a,b   Yin, Huiyong ^a   Kennedy, J Phillip ^a   Meiler, Jens ^a,b   Niswender, Colleen M ^a,b   Jones, Carrie K ^a,b   Conn, P Jeffrey ^a,b   Weaver, C David ^a,b   Lindsley, Craig W ^a,b  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Agonist; Allosteric; Cognition; MAChR; Muscarinic

Indexed keywords

ETHYL 4 (2 BENZAMIDOETHYLAMINO)PIPERIDINE 1 CARBOXYLATE; ETHYL 4 [2 (2 METHYLBENZAMIDO)ETHYLAMINO]PIPERIDINE 1 CARBOXYLATE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M1 RECEPTOR AGONIST; SCOPOLAMINE; UNCLASSIFIED DRUG; VU 0184670; VU 0207811; VU 0357017; VU 0359993; VU 0359995; VU 0360010; VU 0360014;

ALLOSTERISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION; BINDING SITE; BRAIN FUNCTION; CENTRAL NERVOUS SYSTEM; CHOLINERGIC TRANSMISSION; COGNITIVE DEFECT; CONDITIONING; CONTROLLED STUDY; DRUG EFFICACY; DRUG SYNTHESIS; DRUG TARGETING; FEAR; FOREBRAIN; HIGH THROUGHPUT SCREENING; IN VIVO STUDY; LEARNING; MALE; MEMORY; MOUSE; MUTAGENESIS; NONHUMAN; RODENT; SCHIZOPHRENIA; STRUCTURE ACTIVITY RELATION;

RODENTIA;

EID: 77952947252     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn900003h     Document Type: Article

References (44)

1. Levey, A. I. (1993) Immunological localization of M1-M5 muscarinic acetylcholine receptors in peripheral-tissues and brain Life Sci. 52, 441-448
2. Abrams, P., Andersson, K. E., Buccafusco, J. J., Chapple, C., Chet de Groat, W., Fryer, A. D., Kay, G., Laties, A., Nathanson, N. M., Pasricha, P. J. and Wein, A. (2006) Muscarinic receptors: Their distribution and function in body systems, and the implications for treating overactive bladder Br. J. Pharmacol. 148, 565-578
3. Volpicelli, L. A. and Levey, A. I. (2004) Muscarinic acetylcholine receptor subtypes in cerebral cortex and hippocampus Prog. Brain Res. 145, 59-66
4. Felder, C. C., Porter, A. C., Skillman, T. L., Zhang, L., Bymaster, F. P., Nathanson, N. M., Hamilton, S. E., Gomeza, J., Wess, J. and McKinzie, D. L. (2001) Elucidating the role of muscarinic receptors in psychosis Life Sci. 68 (22-23) 2605-2613
5. Anagnostaras, S. G., Murphy, G. G., Hamilton, S. E., Mitchell, S. L., Rahnama, N. P., Nathanson, N. M. and Silva, A. (2003) Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice Nat. Neurosci. 6, 51-58
6. Wess, J., Eglen, R. M. and Gautam, D. (2007) Muscarinic acetylcholine receptors: Mutant mice provide new insights for drug development Nat. Rev. Drug Discov. 6, 721-733
7. Bartus, R. T. (2000) On neurodegenerative diseases, models, and treatment strategies: Lessons learned and lessons forgotten a generation following the cholinergic hypothesis Exp. Neurol. 163, 495-529
8. Langmead, C. J., Watson, J. and Reavill, C. (2008) Muscarinic acetylcholine receptors as CNS drug targets Pharmacol. Ther. 117, 232-243
9. Fisher, A. (2008) M1 muscarinic agonists target major hallmarks of Alzheimer's Disease - the pivotal role of brain M1 receptors Neurodegener. Dis. 5, 237-240
10. Raedler, T. J., Bymaster, F. P., Tandon, R., Copolov, D. and Dean, B. (2007) Towards a muscarinic hypothesis of schizophrenia Mol. Psychiatry 12, 232-246
11. Shekhar, A., Potter, W. Z., Lightfoot, J., Lienemann, J., Dube, S., Mallinckrodt, C., Bymaster, F. P., McKinzie, D. L. and Felder, C. C. (2008) Selective muscarinic receptor agonist Xanomeline as a novel treatment approach for schizophrenia Am. J. Psychiatry 165, 1033-1039
12. Scarr, E., Sundrarn, S., Keriakous, D. and Dean, B. (2007) Altered hippocampal muscarinic M4, but not M1, receptor expression from subjects with schizophrenia Biol. Psychiatry 61, 1161-1170
13. Heinrich, J. N., Butera, J. A., Carrick, T., Kramer, A., Kowal, D., Lock, T., Marquis, K. L., Pausch, M. H., Popiolek, M., Sun, S. C., Tseng, E., Uveges, A. J. and Mayer, S. C. (2009) Pharmacological comparison of muscarinic ligands: Historical versus more recent muscarinic M1-preferring receptor agonists Eur. J. Pharmacol. 605, 53-56
14. Mirza, N. R., Peters, D. and Sparks, R. G. (2003) Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists CNS Drug Rev. 9 (2) 159-186
15. Marino, M. J., Rouse, S. T., Levey, A. I., Potter, L. T. and Conn, P. J. (1998) Activation of the genetically defined m1 muscarinic receptor potentiates N-methyl-d-aspartate (NMDA) receptor currents in hippocampal pyramidal cells Proc. Natl. Acad. Sci. U.S.A. 95, 11465-11470
16. Sur, C., Mallorga, P. J., Wittmann, M., Jacobson, M. A., Pascarella, D., Williams, J. B., Brandish, P. E., Pettibone, D. J., Scolnick, E. M. and Conn, P. J. (2003) N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-d-aspartate receptor activity Proc. Natl. Acad. Sci. U.S.A. 100, 13674-13679
17. Conn, P. J., Jones, C. K. and Lindsley, C. W. (2009) Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders Trends Pharmacol. Sci. 30, 148-155
18. Jeffrey Conn, P., Christopoulos, A. and Lindsley, C. W. (2009) Allosteric modulators of GPCRs: A novel approach for the treatment of CNS disorders Nat. Rev. Drug Discovery 8, 41-54
19. Pakrasi, S., Colloby, S. J., Firbank, M. J., Perry, E. K., Wyper, D. J., Owens, J., McKeith, I. G., Williams, E. D. and O'Brien, J. T. (2007) Muscarinic acetylcholine receptor status in Alzheimer's disease assessed using (R, R) 123I-QNB SPECT J. Neurol. 254, 907-913
20. Shinoe, T., Matsui, M., Taketo, M. M. and Manabe, T. (2005) Modulation of synaptic plasticity by physiological activation of M1 muscarinic acetylcholine receptors in the mouse hippocampus J. Neurosci. 25, 11194-11200
21. Jones, C. K., Brady, A. E., Davis, A. A., Xiang, Z., Bubser, M., Tantawy, M. N., Kane, A. S., Bridges, T. M., Kennedy, J. P., Bradley, S. R., Peterson, T. E., Ansari, M. W., Baldwin, R. M., Kessler, R. M., Deutch, A. Y., Lah, J. J., Levey, A. I., Lindsley, C. W. and Conn, P. J. (2008) Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats J. Neurosci. 28, 10422-10433
22. Bodick, N. C., Offen, W. W., Levey, A. I., Cutler, N. R., Gauthier, S. G., Satlin, A., Shannon, H. E., Tollefson, G. D., Rasmussen, K., Bymaster, F. P., Hurley, D. J., Potter, W. Z. and Paul, S. M. (1997) Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease Arch. Neurol. 54, 465-473
23. Caccamo, A., Oddo, S., Billings, L. M., Green, K. N., Martinez-Coria, H., Fisher, A. and LaFerla, F. M. (2006) M1 receptors play a central role in modulating AD-like pathology in transgenic mice Neuron 49, 671-682
24. Lewis, J., Lebois, E. P. and Lindsley, C. W. (2008) Allosteric modulators of kinases and GPCRs. Design principles and structural diversity Curr. Opin. Chem. Biol. 12, 269-280
25. Bridges, T. M. and Lindsley, C. W. (2008) G-Protein-coupled receptors: From classical modes of modulation to allosteric mechanisms ACS Chem. Biol. 3, 530-541
26. 1 muscarinic receptors reveals multiple modes of activity Mol. Pharmacol. 75 (3) 577-588
27. 4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats J. Pharmacol. Exp. Ther. 327 (3) 941-953
28. Bridges, T. M., Marlo, J. E., Niswender, C. M., Jones, C. K., Jadhav, S. B., Gentry, P. R., Plumley, H. K., Weaver, C. D. and Conn, P. J. (2009) Discovery of the first highly M5-preferring muscarinic acetylcholine receptor ligand, an M5 positive allosteric modulator derived from a series of 5-trifluoromethoxy N -benzyl isatins J. Med. Chem. 52, 3445-3448
29. Langmead, C. J., Fry, V. A. H., Forbes, I. T., Branch, C. L., Christopoulos, A. C., Wood, M. D. and Herdon, H. J. (2006) Probing the molecular mechanism of interaction between 4-n-butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl] -piperidine (AC-42) and the muscarinic M1 receptor: Direct pharmacological evidence that AC-42 is an allosteric agonist Mol. Pharmacol. 69, 236-246
30. Langmead, C. J., Austin, N. E., Branch, C. L., Brown, J. T., Buchanan, K. A., Davies, C. H., Forbes, I. T., Fry, V. A. H., Hagan, J. J., Herdon, J. J., Jones, G. A., Jeggo, R., Kew, J. N. C., Mazzali, A., Melarange, R., Patel, N., Pardoe, J., Randall, A. D., Roberts, C., Roopun, A., Starr, K. R., Teriakidis, A., Wood, M. D., Whittington, M., Wu, Z. and Watson, J. (2008) Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1 Br. J. Pharmacol. 154, 1104-1115
31. Spalding, T. A., Trotter, C., Skjaerbaek, N., Messier, T. L., Currier, E. A., Burstein, E. S., Li, D., Hacksell, U. and Brann, M. R. (2002) Discovery of an ectopic activation site on the M1 muscarinic receptor Mol. Pharmacol. 61, 1297-1302
32. Lebon, G., Langmead, C. J., Tehan, B. G. and Hulme, E. C. (2009) Mutagenic mapping suggests a novel binding mode for selective agonists of M1 muscarinic acetylcholine receptors Mol. Pharmacol. 75, 331-341
33. Chan, W. Y., McKinzie, D. L., Bose, S., Mitchell, S. N., Witkin, J. M., Thompson, R. C., Christopoulos, A. C., Lazareno, S., Birdsall, N. J. M., Bymaster, F. P. and Felder, C. C. (2008) Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia Proc. Natl. Acad. Sci. U.S.A. 105, 10978-10983
34. Malenka, R. C. and Bear, M. F. (2004) LTP and LTD: An embarrassment of riches Neuron 44, 5-21
35. Origlia, N., Kuczewski, N., Aztiria, E., Gautam, D., Wess, J. and Domenici, L. (2006) Muscarinic acetylcholine receptor knockout mice show distinct synaptic plasticity impairments in the visual cortex J. Physiol.-London 577, 829-840
36. McCoy, P., Norton, T. T. and McMahon, L. L. (2008) Layer 2/3 synapses in monocular and binocular regions of tree shrew visual cortex express mAChR-dependent long-term depression and long-term potentiation J. Neurophysiol. 100, 336-345
37. Ibach, B. and Haen, E. (2004) Acetylcholinesterase inhibition in Alzheimer's Disease Curr. Pharm. Des. 10, 231-251
38. Lleo, A., Greenberg, S. M. and Growdon, J. H. (2006) Current pharmacotherapy for Alzheimer's Disease Annu. Rev. Med. 57, 513-533
39. 1 mAChR) antagonist reduces seizures without impairing hippocampal-dependent learning. Mol. Pharmacol. Epub April 30, 2009. DOI: 10.1124/mol.109.056531.
40. MLPCN Web site: https://mli.nih.gov/mli/mlpcn/.
41. Kennedy, J. P., Williams, L., Bridges, T. M., Daniels, R. N., Weaver, D. and Lindsley, C. W. (2008) Application of combinatorial chemistry science on modern drug discovery J. Comb. Chem. 10 (3) 345-354
42. 4 mAChR modulates hippocampal synaptic transmission Nat. Chem. Biol. 4, 42-50
43. Cherezov, V., Rosenbaum, D. M., Hanson, M. A., Rasmussen, S. G. F., Thian, F. S., Kobilka, T. S., Choi, H., Kuhn, P., Weis, W. I., Kobilka, B. K. and Stevens, R. C. (2007) High-resolution crystal structure of an engineered human β2-adrenergic G protein-coupled receptor Science 318, 1258-1265 (Pubitemid 350172884)
44. Meiler, J. and Baker, D. ROSETTALIGAND: protein-small molecule docking with full side-chain flexability Proteins 65 (3) 538-548